Humacyte Ownership | Who Owns Humacyte?

Overview ForecastFinancials Chart Transcripts

Humacyte Ownership Summary

Humacyte is owned by 18.57% institutional investors, 26.93% insiders, and 54.49% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 6.74% of HUMA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.26% of its assets in Humacyte shares.

HUMA Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Humacyte	18.57%	26.93%	54.49%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock funding, inc. /de	8.05M	6.74%	$40.64M
Blackrock	7.14M	6.60%	$34.27M
Vanguard group	5.60M	4.69%	$28.29M
State street	4.61M	3.86%	$23.28M
Woodline partners lp	2.85M	2.39%	$14.39M
Geode capital management	2.14M	1.79%	$10.79M
Centerbook partners lp	1.28M	1.07%	$6.46M
Ubs group	1.12M	0.94%	$5.66M
Two sigma investments, lp	919.10K	0.77%	$4.64M
Millennium management	918.85K	0.77%	$4.64M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Endowment wealth management	104.11K	0.42%	$625.75K
Centerbook partners lp	1.28M	0.39%	$6.46M
Wealth effects	121.40K	0.22%	$613.07K
Lji wealth management	185.00K	0.18%	$934.25K
Woodline partners lp	2.85M	0.10%	$14.39M
Clarus wealth advisors	41.06K	0.09%	$180.27K
United asset strategies	184.21K	0.09%	$930.25K
Clough capital partners l p	104.40K	0.06%	$527.22K
Gsa capital partners llp	147.44K	0.06%	$745.00K
Ars investment partners	99.42K	0.05%	$502.07K

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	7.14M	0.00%	2.35M
Woodline partners lp	2.85M	0.10%	2.00M
Centerbook partners lp	1.28M	0.39%	1.28M
Ubs group	1.12M	0.00%	937.54K
Brevan howard capital management lp	876.34K	0.03%	846.07K

Top Sellers

Holder	Shares	% Assets	Change
Aigh capital management	-	-	-2.16M
Sio capital management	-	-	-2.00M
Voloridge investment management	499.20K	0.01%	-760.74K
Renaissance	-	-	-600.30K
Prescott general partners	-	-	-568.25K

New Positions

Holder	Shares	% Assets	Change	Value
Centerbook partners lp	1.28M	0.39%	1.28M	$6.46M
Franklin resources	433.48K	0.00%	433.48K	$2.19M
First trust advisors lp	340.55K	0.00%	340.55K	$1.72M
Lji wealth management	185.00K	0.18%	185.00K	$934.25K
Walleye capital	106.70K	0.00%	106.70K	$538.83K

Sold Out

Holder	Change
National bank of canada /fi/	-2.00
Org partners	-10.00
Russell investments group	-35.00
Bare financial services	-104.00
Gamma investing	-112.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2024	87	-42.38%	22,175,982	-38.04%	18	2.07%	52	-41.57%	18	-30.77%
Sep 30, 2024	149	14.62%	35,789,080	14.71%	29	3.61%	90	-8.16%	25	78.57%
Jun 30, 2024	129	27.72%	31,200,461	33.99%	28	5.69%	97	110.87%	14	-58.82%
Mar 31, 2024	101	12.22%	23,285,302	30.90%	22	7.61%	46	2.22%	34	100.00%
Dec 31, 2023	90	4.65%	17,788,291	7.17%	17	6.67%	45	-13.46%	17	30.77%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	2.90M	2.26%	-
iShares Russell 2000 ETF	2.35M	1.52%	-20.41K
SPDR® S&P Biotech ETF	2.27M	1.46%	-24.27K
Vanguard Institutional Extnd Mkt Idx Tr	1.55M	1.20%	2.52K
Nuveen Quant Small Cap Equity R6	728.27K	0.61%	-
Fidelity Small Cap Index	881.75K	0.57%	-16.51K
iShares Russell 2000 Growth ETF	783.80K	0.51%	-3.73K
MEDICAL BioHealth EUR Acc	718.45K	0.46%	195.14K
iShares Biotechnology ETF	666.85K	0.43%	-7.43K
State St Russell Sm/Mid Cp® Indx NL Cl C	547.72K	0.43%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 14, 2025	Scheessele William John	Chief Commercial Officer	Buy	$10.00K
Apr 10, 2025	Sander Dale A.	CFO and Chief Corp. Deve. Off.	Buy	$30.60K
Apr 10, 2025	Parikh Shamik J	Chief Medical Officer	Buy	$11.63K
Apr 08, 2025	Sebelius Kathleen	-	Buy	$66.00K
Apr 08, 2025	Green Charles Bruce	-	Buy	$7.74K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	6	-
2025 Q1	-	-
2024 Q4	3	6
2024 Q3	3	13
2024 Q2	8	18

HUMA Ownership FAQ

Who Owns Humacyte?

Humacyte shareholders are primarily institutional investors at 18.57%, followed by 26.93% insiders and 54.50% retail investors. The average institutional ownership in Humacyte's industry, Biotech Stocks , is 68.48%, which Humacyte falls below.

Who owns the most shares of Humacyte?

Humacyte’s largest shareholders are Blackrock funding, inc. /de (8.05M shares, 6.74%), Blackrock (7.14M shares, 6.60%), and Vanguard group (5.6M shares, 4.69%). Together, they hold 18.03% of Humacyte’s total shares outstanding.

Does Blackrock own Humacyte?

Yes, BlackRock owns 6.60% of Humacyte, totaling 7.14M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 34.27M$. In the last quarter, BlackRock increased its holdings by 2.35M shares, a 49.10% change.

Who is Humacyte’s biggest shareholder by percentage of total assets invested?

Endowment wealth management is Humacyte’s biggest shareholder by percentage of total assets invested, with 0.42% of its assets in 104.11K Humacyte shares, valued at 625.75K$.

Who is the top mutual fund holder of Humacyte shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Humacyte shares, with 2.26% of its total shares outstanding invested in 2.9M Humacyte shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools